<DOC>
	<DOCNO>NCT00516100</DOCNO>
	<brief_summary>Pemetrexed FDA-approved treatment advance lung cancer response rate still low . Bortezomib currently approve treat myeloma patient already treat . Currently , multiple study actively investigate well bortezomib work drug . This study test much bortezomib give advanced lung cancer patient already receive one treatment . This study also see well bortezomib pemetrexed work together treat lung cancer patient .</brief_summary>
	<brief_title>Bortezomib ( Velcade ) + Pemetrexed ( Alimta ) Advanced NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Unresectable locally advanced ( Stage IIIB ) metastatic ( Stage IV ) NSCLC receive one prior platinumbased chemotherapy regimen . One prior treatment biologically target agent acceptable Stable , previously treat , brain metastasis allow clinically stable without steroid treatment 10 day . ECOG performance status 0 1 . Measurable and/or evaluable indicator lesion ( ) . Adequate hematologic , renal hepatic function Patient legally consent age Patient lifeexpectancy &gt; 2 month . Voluntary write informed consent performance studyrelated procedure Female patient either postmenopausal surgically sterilize willing use acceptable method birth control duration study . Male patient agree use acceptable method contraception duration study . Prior treatment pemetrexed ( Alimta ) Bortezomib ( Velcade ) . Patient treat another cancer within 3 year enrollment , exception basal cell carcinoma cervical cancer situ . Peripheral neuropathy NCI grade &gt; 2 . Symptomatic uncontrolled brain metastasis . Radiation therapy major bone marrow ( &gt; 10 % bone marrow ) area target lesion within 30 day prior study entry . Patient receive investigational drug 14 day enrollment . Serious medical psychiatric illness likely interfere participation clinical study . Any systemic therapy within 21 day prior study entry . Patient known human immunodeficiency virus ( HIV ) positive . Patient significant cardiac event within 6 month enrollment History arrhythmia Congenital long QT syndrome 1st degree relative unexplained sudden death 40 year age . QT prolongation medication require discontinuation medication . Presence leave bundle branch block ( LBBB ) . QTc â‰¥480 msec great screen ECG . Patient hypersensitivity bortezomib , boron mannitol . Female patient pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>NSCLC</keyword>
</DOC>